$IPSI
Innovative Payment Solutions, Inc. Stock $ipsi

$ipsi Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023066736 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	-$28.00	$5.00
YoY Change
Cost Of Revenue	$387.00	$284.00
YoY Change
Gross Profit	-$415.00	-$279.00
YoY Change
Gross Profit Margin		-5580.0%
Selling, General & Admin	$750.0K	$1.058M
YoY Change	-72.44%	32.94%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$100.0K	$139.0K
YoY Change	387.8%	2991.28%
% of Gross Profit
Operating Expenses	$846.1K	$1.197M
YoY Change	-69.14%	49.57%
Operating Profit	-$846.5K	-$1.197M
YoY Change	-69.13%	49.61%
Interest Expense	$83.83K	$69.32K
YoY Change	149.79%	-124.13%
% of Operating Profit
Other Income/Expense, Net	-$20.00K	$0.00
YoY Change	-96.68%
Pretax Income	-$1.015M	-$2.652M
YoY Change	-69.34%	143.89%
Income Tax
% Of Pretax Income
Net Earnings	-$1.015M	-$3.174M
YoY Change	-69.26%	195.45%
Net Earnings / Revenue		-63484340.0%
Basic Earnings Per Share	-$0.08	-$0.01
Diluted Earnings Per Share	-$0.08	-$0.01
COMMON SHARES
Basic Shares Outstanding	379.1M shares	376.9M shares
Diluted Shares Outstanding	12.79M shares	377.9M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.00K	$46.79K
YoY Change	-98.52%	-98.15%
Cash & Equivalents	$19.40K	$373.8K
Short-Term Investments
Other Short-Term Assets	$49.41K	$19.08K
YoY Change	-63.09%	-28.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$68.81K	$254.6K
YoY Change	-95.37%	-90.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.569K	$14.86K
YoY Change	-85.56%	-24.97%
Goodwill
YoY Change
Intangibles	$0.00	$1.192M
YoY Change	-100.0%	23.53%
Long-Term Investments	$704.3K	$306.8K
YoY Change	40.87%	-38.63%
Other Assets	$20.00K	$84.57K
YoY Change	-57.97%	143.02%
Total Long-Term Assets	$726.9K	$1.598M
YoY Change	-59.57%	5.18%
TOTAL ASSETS
Total Short-Term Assets	$68.81K	$254.6K
Total Long-Term Assets	$726.9K	$1.598M
Total Assets	$795.7K	$1.853M
YoY Change	-75.78%	-54.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.596M	$1.387M
YoY Change	177.72%	242.7%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$4.540M	$3.900M
YoY Change	105.36%	117.03%
Long-Term Debt Due	$0.00	$3.280K
YoY Change
Total Short-Term Liabilities	$7.485M	$8.303M
YoY Change	114.1%	200.96%
LONG-TERM LIABILITIES
Long-Term Debt	$160.0K	$158.4K
YoY Change	-1.57%	-1.73%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$158.3K	$158.4K
YoY Change	-2.64%	-1.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.485M	$8.303M
Total Long-Term Liabilities	$158.3K	$158.4K
Total Liabilities	$7.643M	$8.462M
YoY Change	108.91%	189.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.86M	-$55.85M
YoY Change	17.75%	24.14%
Common Stock	$1.303K	$37.91K
YoY Change	-96.54%	3.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.848M	-$6.609M
YoY Change
Total Liabilities & Shareholders Equity	$795.7K	$1.853M
YoY Change	-75.78%	-54.57%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.015M	-$3.174M
YoY Change	-69.26%	195.45%
Depreciation, Depletion And Amortization	$100.0K	$139.0K
YoY Change	387.8%	2991.28%
Cash From Operating Activities	-$160.0K	-$244.9K
YoY Change	-81.56%	-64.6%
INVESTING ACTIVITIES
Capital Expenditures	$40.00K
YoY Change	-113.41%
Acquisitions
YoY Change
Other Investing Activities	-$750.0K	-$215.9K
YoY Change	5763.96%
Cash From Investing Activities	-$800.0K	-$215.9K
YoY Change	157.13%	45.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	920.0K	351.6K
YoY Change		3543.83%
NET CHANGE
Cash From Operating Activities	-160.0K	-244.9K
Cash From Investing Activities	-800.0K	-215.9K
Cash From Financing Activities	920.0K	351.6K
Net Change In Cash	-40.00K	-109.1K
YoY Change	-96.61%	-86.87%
FREE CASH FLOW
Cash From Operating Activities	-$160.0K	-$244.9K
Capital Expenditures	$40.00K
Free Cash Flow	-$200.0K
YoY Change	-64.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Revenues Revenues		usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022Q2	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55648
	dei	Entity Registrant Name EntityRegistrantName	INNOVATIVE PAYMENT SOLUTIONS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-1230229
	dei	Entity Address Address Line1 EntityAddressAddressLine1	56B 5th Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Lot 1 #AT
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel By The Sea
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	93921
	dei	City Area Code CityAreaCode	(866)
	dei	Local Phone Number LocalPhoneNumber	477-4729
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	379075592	shares
CY2023Q2	us-gaap	Cash Cash	46788	usd
CY2022Q4	us-gaap	Cash Cash	373822	usd
CY2023Q2	ipsi	Receivable From Equity Method Investment ReceivableFromEquityMethodInvestment	22103	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	166668	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	19080	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	97042	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	807263	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	254639	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1278127	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14861	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40362	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1191693	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1401491	usd
CY2023Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	64768	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	19800	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	32592	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	306839	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1597961	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1474445	usd
CY2023Q2	us-gaap	Assets Assets	1852600	usd
CY2022Q4	us-gaap	Assets Assets	2752572	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1387412	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	727922	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	33810	usd
CY2023Q2	ipsi	Related Party Payables RelatedPartyPayables	50000	usd
CY2023Q2	us-gaap	Federal Home Loan Bank Advances Current FederalHomeLoanBankAdvancesCurrent	3275	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1012736	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	964268	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	463104	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2837176	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2266602	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3012574	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2550642	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8303173	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6543244	usd
CY2023Q2	ipsi	Federal Relief Loans Non Current FederalReliefLoansNonCurrent	158360	usd
CY2022Q4	ipsi	Federal Relief Loans Non Current FederalReliefLoansNonCurrent	163978	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	158360	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	163978	usd
CY2023Q2	us-gaap	Liabilities Liabilities	8461533	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6707222	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	379075592	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	379075592	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	376901679	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	376901679	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	37908	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	37690	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49200624	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48405921	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55847465	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52399858	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6608933	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3956247	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1597	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6608933	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3954650	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1852600	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2752572	usd
CY2023Q2	us-gaap	Revenues Revenues	5	usd
	us-gaap	Revenues Revenues	438	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	284	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2369	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	-279	usd
	us-gaap	Gross Profit GrossProfit	-1931	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1057631	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	769054	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2007578	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1620580	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	139015	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4497	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	279705	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8993	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1196646	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	773551	usd
	us-gaap	Operating Expenses OperatingExpenses	2287283	usd
	us-gaap	Operating Expenses OperatingExpenses	1629573	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1196925	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-773551	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2289214	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1629573	usd
CY2023Q2	ipsi	Loss On Debt Conversion LossOnDebtConversion	18478	usd
	ipsi	Loss On Debt Conversion LossOnDebtConversion	18478	usd
	ipsi	Penalty On Convertible Debt PenaltyOnConvertibleDebt	-719558	usd
CY2023Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	95079	usd
CY2022Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	45196	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	180300	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	90962	usd
CY2023Q2	ipsi	Amortization Of Debt Discount AmortizationOfDebtDiscount	-88687	usd
	ipsi	Amortization Of Debt Discount AmortizationOfDebtDiscount	-111654	usd
	ipsi	Amortization Of Debt Discount AmortizationOfDebtDiscount	-263200	usd
CY2023Q2	ipsi	Derivative Liability Movement DerivativeLiabilityMovement	1252682	usd
CY2022Q2	ipsi	Derivative Liability Movement DerivativeLiabilityMovement	242102	usd
	ipsi	Derivative Liability Movement DerivativeLiabilityMovement	311932	usd
	ipsi	Derivative Liability Movement DerivativeLiabilityMovement	149941	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2651851	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1060849	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2911578	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2853234	usd
CY2023Q2	ipsi	Income Loss From Continuing Operations After Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsAfterIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2651851	usd
CY2022Q2	ipsi	Income Loss From Continuing Operations After Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsAfterIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1060849	usd
	ipsi	Income Loss From Continuing Operations After Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsAfterIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2911578	usd
	ipsi	Income Loss From Continuing Operations After Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsAfterIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2853234	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1381	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1381	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2653232	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1060849	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2912959	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2853234	usd
CY2023Q2	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	-25561	usd
CY2022Q2	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	-26483	usd
	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	-40821	usd
	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	-44344	usd
CY2023Q2	ipsi	Loss On Disposal Of Subsidiary And Investment LossOnDisposalOfSubsidiaryAndInvestment	-495424	usd
	ipsi	Loss On Disposal Of Subsidiary And Investment LossOnDisposalOfSubsidiaryAndInvestment	-495424	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-520985	usd
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-26483	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-536245	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-44344	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3174217	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1087332	usd
	us-gaap	Profit Loss ProfitLoss	-3449204	usd
	us-gaap	Profit Loss ProfitLoss	-2897578	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12977	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1597	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-21729	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3174217	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1074355	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3447607	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2875849	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	377905023	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367901679	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	377403351	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367901679	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3954650	usd
CY2023Q1	ipsi	Stock Issued During Period Value Fair Value Of Warrants Issued StockIssuedDuringPeriodValueFairValueOfWarrantsIssued	251856	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	130671	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-274987	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3847110	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	43478	usd
CY2023Q2	ipsi	Stock Issued During Period Value Fair Value Of Warrants Issued StockIssuedDuringPeriodValueFairValueOfWarrantsIssued	130025	usd
CY2023Q2	ipsi	Fair Value Of Warrants Issued For Equity Method Investments FairValueOfWarrantsIssuedForEquityMethodInvestments	108220	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	130671	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3174217	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6608933	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3731312	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	94466	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	62766	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1810246	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2078298	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9653	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	94462	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	62766	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1087332	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1157847	usd
	us-gaap	Profit Loss ProfitLoss	-3449204	usd
	us-gaap	Profit Loss ProfitLoss	-2897578	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-536245	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-44344	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2912959	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2853234	usd
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	-311932	usd
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	-149941	usd
	us-gaap	Depreciation Depreciation	279705	usd
	us-gaap	Depreciation Depreciation	8993	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	111654	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	263200	usd
	ipsi	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	18478	usd
	ipsi	Penalty On Convertible Debt PenaltyOnConvertibleDebt	-719558	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1381	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	261342	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	314460	usd
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	22103	usd
	us-gaap	Increase Decrease In Accounts Receivable From Securitization IncreaseDecreaseInAccountsReceivableFromSecuritization	-18570	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-77957	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-58312	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	659490	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-63881	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	50000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	176107	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2712	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-968446	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1399939	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	35287	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-52734	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-933159	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1452673	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	44405	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	290290	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-244405	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-290290	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-36231	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-37510	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-280636	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-327800	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	900000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	11840	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1147063	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2342	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	885818	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1147063	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	9653	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	885818	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1137410	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-327977	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2917883	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	374765	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5449751	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46788	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2531868	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	373822	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5367551	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	943	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	82200	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	374765	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	5449751	usd
CY2023Q2	us-gaap	Cash Cash	46788	usd
CY2022Q2	us-gaap	Cash Cash	2520060	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Cash DisposalGroupIncludingDiscontinuedOperationCash	11808	usd
CY2023Q2	us-gaap	Cash Including Discontinued Operations CashIncludingDiscontinuedOperations	46788	usd
CY2022Q2	us-gaap	Cash Including Discontinued Operations CashIncludingDiscontinuedOperations	2531868	usd
	us-gaap	Interest Paid InterestPaid	4191	usd
	us-gaap	Interest Paid InterestPaid	88250	usd
	ipsi	Fair Value Of Warrants Issued With Convertible Notes FairValueOfWarrantsIssuedWithConvertibleNotes	381881	usd
	ipsi	Conversion Of Convertible Debt To Equity ConversionOfConvertibleDebtToEquity	25000	usd
	ipsi	Fair Value Of Warrants Issued For Equity Method Investments FairValueOfWarrantsIssuedForEquityMethodInvestments	108220	usd
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	621920	shares
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2500	shares
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	500000	shares
CY2019Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	32047817	shares
CY2019Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2250000	shares
CY2019Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2250000	shares
CY2019Q4	ipsi	Percentage Of Shares Vivi PercentageOfSharesVivi	0.09	pure
CY2023Q2	ipsi	Membership Interest MembershipInterest	0.1111	pure
CY2023Q2	ipsi	Tranche Paid TranchePaid	200000	usd
CY2021Q3	ipsi	Percentage Of Remaining Shares Owned PercentageOfRemainingSharesOwned	0.49	pure
CY2023Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	30000000	shares
CY2023Q2	ipsi	Fintech Shares FintechShares	250000	usd
CY2023Q2	ipsi	Percentage Of Credits Against Invoices PercentageOfCreditsAgainstInvoices	0.20	pure
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in"><b>c)</b></td> <td style="text-align: justify"><b>Use of Estimates</b></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="background-color: white">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions, which are evaluated on an ongoing basis, that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to, the estimated useful lives for plant and equipment, the fair value of long-lived investments, the fair value of warrants and stock options granted for services or compensation, estimates of the probability and potential magnitude of contingent liabilities, derivative liabilities, the valuation allowance for deferred tax assets due to continuing operating losses and the allowance for doubtful accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="background-color: white">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in"><b>f)</b></td> <td style="text-align: justify"><b>Risks and Uncertainties</b></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="background-color: white">The Company’s operations are and will be subject to significant risks and uncertainties including financial, operational, regulatory, and other risks, including the potential risk of business failure. These risks include, without limitation, risks associated with (i) launching and scaling the Company’s IPSIPay and IPSIPay Express products and the use by customers of such products, (ii) developing and implementing successful marketing campaigns and other strategic initiatives; (iii) competition, (iv) compliance with applicable laws, rules and regulations (including those related to fund remittance); (v) the Company’s outstanding indebtedness, including the Company’s ability to repay or extend the maturity of such indebtedness (see notes 11 and 12); (vi) inflation and other economic factors and (vii) the Company’s ability to obtain necessary financing. These conditions may not only limit the Company’s access to capital, but also make it difficult for its customers, vendors and the Company to accurately forecast and plan future business activities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="background-color: white">The Company’s results may also be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things. Many of these risks are beyond the Company’s control and are unpredictable. The Company may be unable to adequately manage such risks and similar risks, which could impair the viability of the Company.</span></p>
	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	308220	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1381	usd
	ipsi	Joint Venture Total JointVentureTotal	306839	usd
CY2023Q2	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	2342	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q2	ipsi	Federally Insured Limit FederallyInsuredLimit	0	usd
CY2022Q4	ipsi	Federally Insured Limit FederallyInsuredLimit	120580	usd
CY2023Q2	ipsi	Equity Methods Investment Ownership Percentage EquityMethodsInvestmentOwnershipPercentage	0.20	pure
	ipsi	Schedule Of Estimated Useful Lives Of Assets ScheduleOfEstimatedUsefulLivesOfAssets	<span style="background-color: white">Plant and equipment is stated at cost, less accumulated depreciation. Plant and equipment with costs greater than $1,000 are capitalized and depreciated. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of the assets are as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 49%; border-bottom: black 1.5pt solid"><b>Description</b></td> <td style="width: 2%"> </td> <td style="width: 49%; border-bottom: black 1.5pt solid"><b>Estimated Useful Life</b></td></tr> <tr> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td>Kiosks (not used in the Company’s current business)</td> <td> </td> <td>7 years</td></tr> <tr> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td>Computer equipment</td> <td> </td> <td>3 years</td></tr> <tr> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td>Office equipment</td> <td> </td> <td>10 years</td></tr> </table>
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1000	usd
	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	438	usd
	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	0	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	2775	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	147656	usd
CY2023Q2	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	30000000	shares
CY2023Q2	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	250000	usd
CY2023Q2	us-gaap	Credit Derivative Liquidation Proceeds Percentage CreditDerivativeLiquidationProceedsPercentage	0.20	pure
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	339	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	327211	usd
CY2023Q2	ipsi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Security Deposit BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesSecurityDeposit	15000	usd
CY2023Q2	ipsi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Investment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestment	500000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	842211	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	842550	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	97126	usd
CY2023Q2	ipsi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net Assets Sold BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAssetsSold	745424	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	250000	usd
CY2023Q2	ipsi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net Loss On Disposal BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetLossOnDisposal	495424	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Cash DisposalGroupIncludingDiscontinuedOperationCash	943	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent	291320	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	500000	usd
CY2022	ipsi	Security Deposits SecurityDeposits	15000	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	807263	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	33810	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	33810	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	25561	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	26483	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	40821	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	44344	usd
CY2023Q2	us-gaap	Production Tax Expense ProductionTaxExpense	25561	usd
CY2022Q2	us-gaap	Production Tax Expense ProductionTaxExpense	26483	usd
	us-gaap	Production Tax Expense ProductionTaxExpense	40821	usd
	us-gaap	Production Tax Expense ProductionTaxExpense	44344	usd
CY2023Q2	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-25561	usd
CY2022Q2	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-26483	usd
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-40821	usd
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-44344	usd
CY2023Q2	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-25561	usd
CY2022Q2	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-26483	usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-40821	usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-44344	usd
CY2023Q2	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	13978	usd
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	3275	usd
CY2021Q3	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	250000	usd
CY2021Q3	ipsi	Fintech Percentage FintechPercentage	0.51	pure
CY2021Q3	ipsi	Owned Frictionless Financial Technologies OwnedFrictionlessFinancialTechnologies	0.49	pure
CY2022	ipsi	Additional Amount Of Software AdditionalAmountOfSoftware	41320	usd
	ipsi	Additional Amount Of Software AdditionalAmountOfSoftware	35891	usd
CY2021	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	375000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	1127400	usd
	us-gaap	Payments For Software PaymentsForSoftware	44405	usd
	us-gaap	Finite Lived Intangible Assets Cost Incurred To Renew Or Extend FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend	1546805	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-355112	usd
CY2023Q2	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	1191693	usd
CY2022Q4	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	1401491	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	128348	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	254204	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023Q2	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	200000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	108220	usd
	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The lease commenced on April 1, 2021 and is for a twelve month period, terminating on April 1, 2022.
	us-gaap	Lease Cost LeaseCost	4800	usd
CY2023Q1	ipsi	Monthly Rent MonthlyRent	5088	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	30528	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	28800	usd
	ipsi	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-30528	usd
	ipsi	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-28800	usd
	ipsi	Remaining Lease Term Operating Lease RemainingLeaseTermOperatingLease	Monthly
	ipsi	Remaining Lease Term Operating Lease RemainingLeaseTermOperatingLease	Monthly
CY2020Q3	ipsi	Disaster Loan Amount DisasterLoanAmount	150000	usd
CY2020Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.0375	pure
CY2020Q3	us-gaap	Interest And Fee Income Loans Consumer Installment Credit Card InterestAndFeeIncomeLoansConsumerInstallmentCreditCard	731	usd
	ipsi	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity		usd
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	500500	usd
CY2021Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.125	pure
CY2021Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	2486957	shares
CY2021Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.24
	us-gaap	Notes Issued1 NotesIssued1	964000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	964000	usd
	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	48736	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	1012736	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	964268	usd
CY2023Q2	us-gaap	Other Noninterest Expense OtherNoninterestExpense	24368	usd
CY2022Q2	us-gaap	Other Noninterest Expense OtherNoninterestExpense	0	usd
	us-gaap	Other Noninterest Expense OtherNoninterestExpense	48468	usd
	us-gaap	Other Noninterest Expense OtherNoninterestExpense	0	usd
CY2022Q1	us-gaap	Debt Instrument Maturity Date Range End1 DebtInstrumentMaturityDateRangeEnd1	2022-08-16
CY2022Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	3000000	shares
CY2023Q2	us-gaap	Shares Issued SharesIssued	3000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	39130435	shares
CY2021Q1	ipsi	Non Convertible Promissory Note NonConvertiblePromissoryNote	482000	usd
CY2021Q1	us-gaap	Debt Instrument Maturity Date Range End1 DebtInstrumentMaturityDateRangeEnd1	2023-12-30
CY2021Q1	ipsi	Debt Instruments Interest Rate Stated Percentage DebtInstrumentsInterestRateStatedPercentage	0.10	pure
CY2021Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	51901711	shares
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.06
CY2022Q4	ipsi	Aggregate Amount AggregateAmount	2264784	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0115
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	836414	usd
	ipsi	Black Scholes Valuation Model BlackScholesValuationModel	1499577	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	238182	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	920392	usd
CY2023Q2	us-gaap	Senior Notes SeniorNotes	964000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11	usd
	ipsi	Holders Amounting HoldersAmounting	841003	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	69320	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	43793	usd
	us-gaap	Interest Expense InterestExpense	129057	usd
	us-gaap	Interest Expense InterestExpense	88172	usd
CY2023Q2	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	88687	usd
CY2022Q2	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	111654	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	263200	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	18478	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1800	usd
CY2021Q1	ipsi	Repayment Of Notes Payables RepaymentOfNotesPayables	62700	usd
CY2021Q1	us-gaap	Shares Issued SharesIssued	17.33	shares
	ipsi	Purchase Of Aggregate Shares PurchaseOfAggregateShares	66335391	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0115
CY2023Q2	ipsi	Debt Instruments Interest Rate Stated Percentage DebtInstrumentsInterestRateStatedPercentage	0.08	pure
	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	0.0115
	ipsi	Beneficially Own Of Percentage BeneficiallyOwnOfPercentage	0.0499	pure
	ipsi	Limitation Exceeds Percentage LimitationExceedsPercentage	0.0999	pure
	ipsi	Rachet Provision RachetProvision	474614	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	360491	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	150000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	2550642	usd
CY2022	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	407161	usd
	ipsi	Derivative Financial Liability Arising From Convertible Note DerivativeFinancialLiabilityArisingFromConvertibleNote	150000	usd
CY2022	ipsi	Derivative Financial Liability Arising From Convertible Note DerivativeFinancialLiabilityArisingFromConvertibleNote	238182	usd
CY2022	ipsi	Derivativefinancialliabilityarisingonnoteamendmentincludedinlossonconvertiblenotes Derivativefinancialliabilityarisingonnoteamendmentincludedinlossonconvertiblenotes	2317051	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	311932	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-411752	usd
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	3012574	usd
CY2022	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	2550642	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	379075592	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	376901679	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2173913	shares
CY2023Q2	ipsi	Conversion Of Convertible Debt To Equity ConversionOfConvertibleDebtToEquity	25000	usd
	ipsi	Restricted Stock Granted Shares RestrictedStockGrantedShares	23495000	shares
	ipsi	Restricted Stock Granted Weighted Average Fair Value Per Share RestrictedStockGrantedWeightedAverageFairValuePerShare	0.05
CY2023Q2	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	62766	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	125532	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	(i) a cash endorsement fee of Three Hundred Thousand U.S. Dollars ($300,000 USD), payable as follows: (i) One Hundred Twenty-Five Thousand Dollars ($125,000) upon execution of the Endorsement Agreement, (ii) One Hundred Twenty-Five Thousand Dollars ($125,000) quarterly during the Term, beginning on the 90th day following the Effective Date, and (iii) Fifty Thousand Dollars ($50,000) on or prior to the first anniversary of the Effective Date and (ii) warrants exercisable for an aggregate of Fifteen Million (15,000,000) shares of the Common Stock at an exercise price of $0.0345 per share. The Warrants shall have a three-year term commencing from the Effective Date.
CY2022Q3	ipsi	Expiration Dates ExpirationDates	2027-08-30
CY2022Q4	ipsi	Note Amendment Transaction Description NoteAmendmentTransactionDescription	the Company entered into the December 2022 Note Amendment Transaction, as fully described in note 9 above. In terms of the Note Amendment Transaction the following occurred: ●The warrants issued to Cavalry and Mercer exercisable for 4,973,914 shares of Common Stock (2,486,957 for each of Cavalry and Mercer), were exchanged for two promissory notes of $482,000 each, as disclosed in note 8 above; ●The warrants issued to Cavalry and Mercer on August 30, 2022, were subject to repricing and a full rachet increase in the number of warrants issued, resulting in an increase in the number of warrants by 72,260,870 (36,130,435 to each Cavalry and Mercer) and a reset of the exercise price to $0.0115 per share. The additional warrants were valued at $841,003 using a Black-Scholes valuation model and was expensed in the statement of operations as a component of the loss on convertible debt. ●An additional 13,736,857 warrants previously issued to Mercer, Iroquois Master Fund and Bellridge Capital LP were subject to repricing of the exercise price from a range of $0.05 to $0.15 per share to $0.0115 per share. The change in the fair value of these warrants of $20,079, using a Black-Scholes valuation model was recorded as a component of the loss on convertible debt.
	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.0999	pure
CY2023Q2	us-gaap	Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears PreferredStockPerShareAmountsOfPreferredDividendsInArrears	0.015
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	198926452	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y11M26D
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.0259
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	195176452	shares
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.0259
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P3Y11M26D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	395833	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q3	ipsi	Options Exercisable Shares OptionsExercisableShares	200000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.04
CY2022	ipsi	Amount Of Immediate Expense AmountOfImmediateExpense	31970	usd
CY2022Q2	ipsi	Loss On Disposal Of Subsidiary And Investment LossOnDisposalOfSubsidiaryAndInvestment		usd
	ipsi	Loss On Disposal Of Subsidiary And Investment LossOnDisposalOfSubsidiaryAndInvestment		usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.00
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.01
	ipsi	Share Based Compensation Arrangements By Share Based Payment Award Option Outstanding ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionOutstanding	46316666	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M8D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.15
CY2023Q2	ipsi	Options Exercisable Number Exercisablein OptionsExercisableNumberExercisablein	40483333	shares
CY2023Q2	ipsi	Options Exercisable Weighted Average Exercise Price OptionsExercisableWeightedAverageExercisePrice	0.15
	ipsi	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm	P8Y5M26D
CY2023Q2	ipsi	Intrinsic Value Outstanding Options IntrinsicValueOutstandingOptions	0	usd
CY2022Q2	ipsi	Intrinsic Value Outstanding Options IntrinsicValueOutstandingOptions	0	usd
CY2023Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	94465	usd
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense	94462	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	188928	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	188928	usd
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	545726432	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	545726432	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	79800582	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	79800582	shares
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.01
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.01
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2023Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2022Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent		usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets		usd
CY2022Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets		usd
CY2023Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	ipsi	Related Party Payables RelatedPartyPayables		usd
CY2022Q4	us-gaap	Federal Home Loan Bank Advances Current FederalHomeLoanBankAdvancesCurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest		usd
	us-gaap	Revenues Revenues		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022Q2	ipsi	Loss On Debt Conversion LossOnDebtConversion		usd
	ipsi	Loss On Debt Conversion LossOnDebtConversion		usd
CY2023Q2	ipsi	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
CY2022Q2	ipsi	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
	ipsi	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
CY2022Q2	ipsi	Amortization Of Debt Discount AmortizationOfDebtDiscount		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	ipsi	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable		usd
	us-gaap	Increase Decrease In Accounts Receivable From Securitization IncreaseDecreaseInAccountsReceivableFromSecuritization		usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Cash DisposalGroupIncludingDiscontinuedOperationCash		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	ipsi	Fair Value Of Warrants Issued With Convertible Notes FairValueOfWarrantsIssuedWithConvertibleNotes		usd
	ipsi	Conversion Of Convertible Debt To Equity ConversionOfConvertibleDebtToEquity		usd
	ipsi	Fair Value Of Warrants Issued For Equity Method Investments FairValueOfWarrantsIssuedForEquityMethodInvestments		usd
CY2023Q2	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet		usd
CY2022Q2	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet		usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet		usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet		usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	ipsi	Derivativefinancialliabilityarisingonnoteamendmentincludedinlossonconvertiblenotes Derivativefinancialliabilityarisingonnoteamendmentincludedinlossonconvertiblenotes		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001591913

Files In Submission

Name	View Source	Status
ipsi-20230630_cal.xml	Edgar Link	unprocessable
0001213900-23-066736-index-headers.html	Edgar Link	pending
0001213900-23-066736-index.html	Edgar Link	pending
0001213900-23-066736.txt	Edgar Link	pending
0001213900-23-066736-xbrl.zip	Edgar Link	pending
f10q0623ex10-1_innovativepay.htm	Edgar Link	pending
f10q0623ex10-2_innovativepay.htm	Edgar Link	pending
f10q0623ex31-1_innovativepay.htm	Edgar Link	pending
f10q0623ex31-2_innovativepay.htm	Edgar Link	pending
f10q0623ex32-1_innovativepay.htm	Edgar Link	pending
f10q0623ex32-2_innovativepay.htm	Edgar Link	pending
f10q0623ex4-1_innovativepay.htm	Edgar Link	pending
f10q0623_innovativepay.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ipsi-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ipsi-20230630_lab.xml	Edgar Link	unprocessable
ipsi-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_innovativepay_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ipsi-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IPSI
Innovative Payment Solutions, Inc. Stock $ipsi

2023 Q3 Form 10-Q Financial Statement

#000121390023066736 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IPSI Innovative Payment Solutions, Inc. Stock $ipsi

2023 Q3 Form 10-Q Financial Statement

#000121390023066736 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IPSI
Innovative Payment Solutions, Inc. Stock $ipsi